Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
UTHR Analyst Ratings
Moderate Buy
8 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
UTHR Stock 12 Month Forecast
Average Price Target
$465.56
▲(16.24% Upside)
| Highest Price Target$575.00 | Average Price Target$465.56 | Lowest Price Target$295.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$400→$500
Buy
24.84%
Upside
Reiterated
09/05/25
Oppenheimer
$510→$575
Buy
43.56%
Upside
Reiterated
09/05/25
UBS
$415→$560
Buy
39.82%
Upside
Reiterated
09/04/25
BTIG
―
Hold
―
Reiterated
09/02/25
Cautious Optimism for United Therapeutics Amid TETON-2 Success and Market UncertaintiesWe believe Yutrepia (LQDA [Buy $49 PT]) and TPIP (INSM [Not Rated]) are appropriately benefiting from positive readthrough today, as the topline TETON-2 results further support the long-term value of the entire inhaled treprostinil category.
J.P. Morgan
―
Buy
―
Reiterated
09/02/25
Bank of America Securities
$314→$463
Hold
15.60%
Upside
Reiterated
09/02/25
Morgan Stanley
$328
Hold
-18.11%
Downside
Reiterated
09/02/25
TD Cowen
$400→$500
Buy
24.84%
Upside
Reiterated
09/02/25
Leerink Partners
―
Buy
―
Reiterated
09/02/25
Jefferies
$432→$564
Buy
40.82%
Upside
Reiterated
09/02/25
Promising Developments in United Therapeutics' Tyvaso Drive Buy Rating Amidst IPF Treatment AdvancementsWe raise PT to $564. Bottom line. As we PREVIEWed, TETON-2 study reached our upside case, not only hitting stat sig on 1EP FVC, but achieving clinically meaningful and competitive efficacy. While UTHR will still need TETON-1 results to file sNDA as aligned with the FDA, TETON-2 results could open the possibility of expedited review process such as rolling submission. For data details at ERS (likely with an investor event), we will watch for: 1) comparator arm performance; 2) FVC benefit across subgroups; 3) FVC kinetics (onset, durability); 4) efficacy for pts with/without PH (unclear whether data will be available); 5) efficacy 2EP; 6) detailed AE.
Cantor Fitzgerald
$405
Buy
1.12%
Upside
Reiterated
08/14/25
Wells Fargo
$314→$295
Hold
-26.35%
Downside
Assigned
07/31/25
Argus Research
$375→$345
Buy
-13.86%
Downside
Reiterated
05/06/25
Goldman Sachs
$302→$293
Hold
-26.85%
Downside
Reiterated
02/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$400→$500
Buy
24.84%
Upside
Reiterated
09/05/25
Oppenheimer
$510→$575
Buy
43.56%
Upside
Reiterated
09/05/25
UBS
$415→$560
Buy
39.82%
Upside
Reiterated
09/04/25
BTIG
―
Hold
―
Reiterated
09/02/25
Cautious Optimism for United Therapeutics Amid TETON-2 Success and Market UncertaintiesWe believe Yutrepia (LQDA [Buy $49 PT]) and TPIP (INSM [Not Rated]) are appropriately benefiting from positive readthrough today, as the topline TETON-2 results further support the long-term value of the entire inhaled treprostinil category.
J.P. Morgan
―
Buy
―
Reiterated
09/02/25
Bank of America Securities
$314→$463
Hold
15.60%
Upside
Reiterated
09/02/25
Morgan Stanley
$328
Hold
-18.11%
Downside
Reiterated
09/02/25
TD Cowen
$400→$500
Buy
24.84%
Upside
Reiterated
09/02/25
Leerink Partners
―
Buy
―
Reiterated
09/02/25
Jefferies
$432→$564
Buy
40.82%
Upside
Reiterated
09/02/25
Promising Developments in United Therapeutics' Tyvaso Drive Buy Rating Amidst IPF Treatment AdvancementsWe raise PT to $564. Bottom line. As we PREVIEWed, TETON-2 study reached our upside case, not only hitting stat sig on 1EP FVC, but achieving clinically meaningful and competitive efficacy. While UTHR will still need TETON-1 results to file sNDA as aligned with the FDA, TETON-2 results could open the possibility of expedited review process such as rolling submission. For data details at ERS (likely with an investor event), we will watch for: 1) comparator arm performance; 2) FVC benefit across subgroups; 3) FVC kinetics (onset, durability); 4) efficacy for pts with/without PH (unclear whether data will be available); 5) efficacy 2EP; 6) detailed AE.
Cantor Fitzgerald
$405
Buy
1.12%
Upside
Reiterated
08/14/25
Wells Fargo
$314→$295
Hold
-26.35%
Downside
Assigned
07/31/25
Argus Research
$375→$345
Buy
-13.86%
Downside
Reiterated
05/06/25
Goldman Sachs
$302→$293
Hold
-26.85%
Downside
Reiterated
02/27/25
Best Analysts Covering United Therapeutics
1 Month
xxx
Success Rate
16/22 ratings generated profit
Average Return
+4.38%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +4.38% per trade.
3 Months
xxx
Success Rate
12/15 ratings generated profit
Average Return
+14.18%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +14.18% per trade.
1 Year
Success Rate
12/15 ratings generated profit
Average Return
+20.73%
reiterated a buy rating 7 days ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +20.73% per trade.
2 Years
xxx
Success Rate
21/22 ratings generated profit
Average Return
+38.05%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 95.45% of your transactions generating a profit, with an average return of +38.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
UTHR Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
1
3
3
2
Buy
20
23
28
24
28
Hold
5
7
9
9
10
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
26
32
40
36
40
Each month's total comprises the sum of three months' worth of ratings.
UTHR Financial Forecast
UTHR Stock Forecast FAQ
What is UTHR’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics’s 12-month average price target is 465.56.
What is UTHR’s upside potential, based on the analysts’ average price target?
United Therapeutics has 16.24% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is UTHR a Buy, Sell or Hold?
United Therapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 4 hold ratings and 0 sell ratings.
What is United Therapeutics’s price target?
The average price target for United Therapeutics is 465.56. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $575.00 ,the lowest forecast is $295.00. The average price target represents 16.24% Increase from the current price of $400.52.
The highest analyst price target is $575.00 ,the lowest forecast is $295.00. The average price target represents 16.24% Increase from the current price of $400.52.
What do analysts say about United Therapeutics?
United Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of UTHR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.